BioStock Studio
Aqilion's new program will be Best-in-Class
Aqilion develops treatments for diseases caused by chronic inflammation. In addition to the three projects already in the company's pipeline...
The contribution of sperm to solving involuntary infertility
While male fertility is declining, interest in...
How Oncopeptides' CEO will take the company to positive cash flow
Oncopeptides researches, develops and commercializes treatments for difficult-to-treat...
Alligator Bioscience on the importance of extending life
What can time mean to a person whose...
BioStock Investor Pitch: Biosergen
Biosergen attacks the invisible threat of fungal infections
How big is the threat from fungal infections and the...
Dicot updates on the Phase I study and Q3
This week, Uppsala-based Dicot published its report for...
Xintela's Chairman of the Board on the company's journey
Gregory Batcheller has been chairman of the board of biopharmaceutical company Xintela...
Cereno Scientific about Q4 and the Phase II study
The reporting season is in full swing and the biotechnology company Cereno Scientific...
DanCann Pharma on the path to commercial breakthrough
DanCann Pharma operates in a growing area...
CLS CEO on the issue and upcoming FDA announcement
Medical technology company Clinical Laserthermia Systems is experiencing strong momentum and...
Lumito on the road to a successful launch
Mattias Lundin